

Case Study


Asset Protection in Biologics Manufacturing: The IntuGrow Advantage



intubio.com

Contents

Executive Summary	3
The Strategic Problem	3
The Solution	4
Value Creation	5
Scenario A: Early Detection	5
Scenario B: Early Abort	5
The Investment in IntuGrow	6
Value Beyond Direct Savings	6
Conclusion	7
References	8
Appendix: Detailed Financial Analysis and ROI Calculation	9
Value at Risk	9
Avoidable Costs per Contamination Event	9
Daily Operating Cost [5]	9
IntuGrow Investment Calculation	11



Executive Summary

In downstream biologics manufacturing, time is the ultimate currency. Traditional bioburden testing requires 5 days for a result, by which point contaminated material has already travelled through your purification train, destroying expensive resins and filters, wasting buffer and labour, and sacrificing valuable production capacity [1]. This is not merely a quality discussion; it is an asset-protection problem with direct multimillion-dollar consequences.

IntuGrow Rapid Microbiological Solution transforms bioburden testing from a passive checkpoint into an active, near-real-time asset-protection tool, delivering validated, actionable results in as little as 3 hours. The financial case is compelling: a 10:1 return on investment, self-funding from the first year of operation with a payback period of less than three months.

The Strategic Problem

In monoclonal antibody production, product value compounds with each purification step. The global biologics market reached \$444.40 billion in 2024 [2], with monoclonal antibodies representing its largest and most valuable segment. For a typical large-scale commercial batch, the accumulated investment follows a clear progression:

- Full upstream investment reaches approximately \$3,500,000 by the time the bioreactor harvest is ready.
- After Protein A chromatography, that value increases to \$4,250,000.
- By the post-viral filtration stage, immediately before formulation, the batch represents nearly \$4,750,000 in accumulated investment.

These figures are consistent with published cost structures showing downstream processing drives 50–80% of total manufacturing costs [3].

When contamination occurs, this entire accumulated value is at immediate risk. But the risk extends beyond the batch itself. Industry benchmarks for downstream consumables are well established:

- Chromatography resin costs \$11,000–\$20,000 per liter [4], with a typical manufacturing-scale column containing 10–15 liters. A conservative estimate for resin replacement following contamination is \$150,000 per event.
- Specialty filtration trains, including viral filters and ultrafiltration membranes, add approximately \$80,000.
- Buffer solutions, utilities, and direct labour add \$25,000 per day of continued processing in single use mAb facilities. [5].

Traditional compendial bioburden methods require 3–5 days to return results. The technology is nearly 140 years old and was never designed for modern, high-speed biologics manufacturing. By the time detection occurs, the contamination may have migrated to other unit operations, process intermediates, or production lots [6].

This creates what the industry calls a "run-at-risk" strategy, continuing to process valuable material while waiting days for test results. By the time traditional methods detect contamination, the affected material has already progressed through multiple purification steps, contaminating equipment and consuming expensive consumables along the way.

The Solution

Transforming bioburden testing from a retrospective checkpoint into a real-time decision tool, IntuGrow delivers validated microbiological results for bacterial detection in cell cultures and water and process samples in a matter of hours instead of days. This provides a 4-day head start over traditional methods, a time-to-knowledge advantage where millions in value are protected.

The technology builds on the familiar principle of traditional cultivation, making adoption straightforward for QC laboratories, but replaces human visual inspection with high-resolution 3D optical scanning. This scanning platform detects colony formation when colonies are just 8 µm in diameter, compared to the 300+ µm required for human detection. The result: the same quantitative data microbiologists trust, colony-forming units (CFU), delivered in hours rather than days. [7]

The system accommodates the full range of bioprocess samples [8]:

- Process intermediates and active pharmaceutical ingredients (APIs).
- Water samples including Water for Injection (WFI), rinse water, and treated water.
- Surface swabs for environmental monitoring.
- Mammalian cell cultures with specialized prefiltration to separate cells from bacterial contaminants.

Detection sensitivity reaches as low as 1 CFU per sample for filterable matrices [7]. Samples are non-destructively monitored, meaning colonies remain viable for subsequent identification if required. The software platform provides automated colony counting, continuous growth monitoring with hourly data updates, and is fully 21 CFR Part 11 compliant for regulated environments. For mold detection, historically slow and subjective, IntuGrow tracks hyphal growth at the earliest stages of formation, enabling quantification days before traditional methods [7].

This technology was recently evaluated in an industry-led collaborative study published by Ramos and colleagues, a project facilitated by the National Institute for Innovation in Manufacturing Biopharmaceuticals (NIIMBL) with participation from AstraZeneca, Bristol-Myers Squibb, Genentech, Merck, Pfizer, and Sanofi [6]. The paper notes that IntuGrow achieves detection in 4–10 hours, detects bacteria, yeasts, and molds, and has a limit of detection of 1 colony-forming unit per sample.

It is emphasized how traditional methods create a fundamental disconnect between process execution and quality information, whereas near-real-time results offer a fundamentally more effective tool for understanding and controlling bioprocesses, concluding that adopting rapid microbial methods is essential for protecting purification trains when contamination events occur [6].

This independent evaluation, conducted with leading pharmaceutical companies, reinforces IntuGrow's position as a solution aligned with industry needs.

Value Creation

With daily sampling, bioburden detection does not occur until at least 72 hours have elapsed, since sampling, or 96 hours into the process, by which point affected material has already reached the final step [6]. With IntuGrow, detection occurs before downstream processing begins or very early in purification. Two scenarios illustrate how IntuGrow creates value:

Scenario A: Early Detection

Contamination is present in the harvest hold tank but has not yet entered downstream purification. IntuGrow detects it within hours of sampling [1]. While this batch may still be lost, the early warning prevents contamination from spreading into the purification train. This protects expensive resins and filters from being fouled, avoids weeks of downtime for cleaning and investigation, and ensures the next batch can move forward without delay. For modelling, \$1,500,000 is conservatively used as the value created per event, reflecting protected downstream assets and recovered production time [3][4] [5].

Scenario B: Early Abort

Contamination entered purification but is detected on Day 1 instead of Day 5. The batch cannot be saved, but all downstream consumables and labor are protected. Resin and filter savings total \$230,000 [3] [4], and 4 days of avoided labor and buffer waste add \$100,000 (based on \$25,000 per day [5]), for a total of \$330,000 in value created per event [10].

Scenario	Value per Event	Annualized Value
Early Detection	\$1,500,000	\$375,000
Early Abort	\$330,000	\$82,500
Total Annual Direct Savings		\$457,500

Based on industry benchmarks and client data, we model a conservative contamination frequency of one significant event every 2 years (0.5 events per year), consistent with industry experience for large-scale commercial manufacturing [9]. With equal probability of the two scenarios, the expected annual direct savings are \$457,500.

The Investment in IntuGrow

Component	Cost
Initial system (hardware, software, license, devices, starter consumables)	Contact IntuBio
Per-sample consumables	
Annual consumables (2,000 samples at 40 per week for 50 weeks)	
Annualized system cost (5-year amortization)	
Total annual IntuGrow cost	

Return on Investment

Item	Amount
Gross annual direct savings	\$457,500
Less annual IntuGrow cost	Contact IntuBio
Net annual financial gain	

This represents:

- Benefit-to-cost ratio: 10:1
- Payback period: < 3 months ($\$ \text{ initial investment} / \$ \text{ annual net gain} \times 12 \text{ months}$).
- Positive cash flow from first year of operation (based on modelled assumptions)

Value Beyond Direct Savings

While the direct financial returns are compelling, the strategic benefits of IntuGrow extend further:

Capacity Recovery:

When contamination is detected on Day 1 instead of Day 5, the purification suite is freed 4 days earlier, enabling faster turnaround and increased annual throughput. "Saves 4 days plant capacity after each contamination" [6].

Reduced Investigation Costs:

Each contamination event triggers a lengthy deviation investigation involving quality assurance, operations, and microbiology staff. Faster detection narrows the root cause investigation window and reduces these hidden costs. As noted in industry analysis, automated systems reduce false positives and investigation-related delays [9].

Supply Chain Resilience:

In today's environment, drug shortages have severe consequences for patients and manufacturers alike. Enhanced microbial control reduces the risk of batch loss and strengthens supply chain reliability.

Regulatory Alignment:

The FDA's Process Analytical Technology framework and ICH Q8, Q9, Q10, and Q13 encourage real-time monitoring and control [3]. IntuGrow enables a control strategy that aligns with regulatory expectations for modern manufacturing as it yields near real-time rapid results. These stand to be a far more effective tool for understanding and monitoring the process than a technology wherein detection lags far behind process execution [6].

Conclusion

The evidence is clear. Industry literature confirms that traditional bioburden testing is fundamentally inadequate for protecting high-value biologics manufacturing. Modern times call for adoption of rapid microbial methods and such IntuGrow as a commercially available, validated solution [6].

The financial case is equally clear:

- Annual direct savings potential: \$457,500
- Benefit-to-cost ratio: 10:1
- Payback period: <3 months

IntuGrow pays for itself. It turns quality control from something that just costs money into something that actively protects margins, helps avoid disruptions, and keeps production running smoothly.

In biologics manufacturing, speed is profit.

References

1. IntuBio. Applications of IntuGrow: Rapid Bioburden Testing, Environmental Monitoring. intubio.dk/solutions/
2. Kentley Insights. Biological Product (except Diagnostic) Manufacturing - 2025 U.S. Market Research Report. February 2025.
3. MDPI Pharmaceuticals. Continuous Manufacturing of Recombinant Drugs: Comprehensive Analysis of Cost Reduction Strategies, Regulatory Pathways, and Global Implementation. *Pharmaceuticals* 2025, 18(8), 1157.
4. Parker Bioscience Filtration / Bioprocess Online. The Cost Of Failing To Protect Your Final Biopharmaceutical Product. 2020.
5. Watanabe N, et al. Economic analysis of buffer preparation strategy for single- use bioprocessing of monoclonal antibodies. *EFB Bioeconomy Journal*. 2024;4:100065.
6. Ramos I, Najera M, Schaefer G. Integration of rapid bioburden testing into production quality management systems and process control. NIIMBL- sponsored publication, 2024.
7. IntuBio. Rapid Microbial Testing with IntuGrow: Technology Overview. intubio.dk/rapid-microbial-testing-with-intugrow/
8. IntuBio. Rapid Water Quality Testing and Analysis; Rapid Contamination Detection in Mammalian Cell Cultures. intubio.dk/solutions/
9. PDA Journal of Pharmaceutical Science and Technology. Economic Impact of Rapid Microbial Methods in Pharmaceutical Manufacturing: A Multi- Site Analysis. 2024;78(3):215-228.
10. QYResearch. Global Biopharmaceutical Chromatography Media Market Report. 2025.
11. Romero JJ, Angelo J, Xu X, Husson SM, Ghose S. Modeling and techno-economic analysis of downstream manufacturing process intensification strategies for existing biopharmaceutical facilities. *Journal of Chromatography A*. 2024;1737:465431.

Appendix: Detailed Financial Analysis and ROI Calculation

This section provides a step-by-step breakdown of the mathematics behind IntuGrow's financial case.

Value at Risk

The accumulated investment in a commercial mAb batch is derived from industry cost structures:

Process Stage	Cumulative Investment	Basis
Upstream through harvest	\$3,500,000	Media, bioreactor time, cell culture, initial harvest
Post-Protein A	\$4,250,000	Added value of capture chromatography
Post-viral filtration	\$4,750,000	Added value of polishing, viral clearance, formulation preparation

These figures are conservative relative to published data showing total biologic manufacturing COGS can reach \$12.5–20.4 million for a 250kg batch, with downstream representing 50–80% of total cost. [3]

Avoidable Costs per Contamination Event

Resin Replacement:

- Protein A resin cost: \$11,000–\$20,000 per liter [4] [10]
- Typical column volume: 10–15 liters
- Conservative mid-point: \$150,000

Single-Use Filter Train:

- Viral filters, ultrafiltration membranes, prefilters
- Industry benchmark: \$80,000 [3][11]

Daily Operating Cost [5]

Cost Component	Daily Estimate
Direct labor (operators, QC across 3 shifts)	\$9,000
Buffer materials (WFI, salts, components)	\$6,000
Utilities (HVAC, WFI generation, clean steam)	\$5,000
Opportunity cost (tied-up equipment, suite)	\$5,000
Total Daily Operating Cost	\$25,000

Value Calculations

Scenario A: Early Detection (Batch Rescue)

- Full batch value protected: \$4,750,000
- Downstream consumables saved: \$230,000 (resin + filters) [3][4]
- Days of operation saved at \$25,000/day: 5 days $\times$ \$25,000 = \$125,000 [5]
- Total potential value: \$5,105,000
- Conservative modelled value: \$1,500,000 per event

Scenario B: Early Abort (Loss Mitigation)

- Resin and filter savings: \$230,000
- Avoided labor, buffer, utilities: 4 days $\times$ \$25,000 = \$100,000
- Total value: \$330,000 per event

Step 4: Contamination Frequency and Annualized Savings

- Modeled frequency: 0.5 events per year (1 event every 2 years)
- Scenario probability: 50% each (0.25 events per year per scenario)
- Annualized savings = $(0.25 \times \$1,500,000) + (0.25 \times \$330,000) = \$375,000 + \$82,500 = \$457,500$

This frequency assumption is conservative relative to published benchmarks showing facilities experiencing multiple contamination events annually [9]. Rationale for conservatism: Not all batches achieve full value; some upstream costs may be sunk; we use a fraction of the total to ensure credibility.

IntuGrow Investment Calculation

Component	USD (\$)
Initial system (hardware, software, license, devices, starter consumables)	Contact IntuBio
Per-sample consumables	
Annual consumables (40 samples/week × 50 weeks = 2,000 samples)	
Annualized system cost (5-year straight-line amortization)	
Total Annual Cost	

ROI and Payback Calculations

Benefit-to-Cost Ratio: 10:1

This means every \$1 invested in IntuGrow returns \$10 in direct savings.

Payback Period (initial investment recovery):

$(\$ \text{ initial investment} / \$ \text{ annual net gain}) \times 12 \text{ months} < 3 \text{ months}$

This payback calculation assumes savings begin accruing immediately upon implementation. Even under the most conservative scenario (one contamination event every 5 years), the system pays for itself within the first year.

Step 7: Sensitivity Analysis

Contamination Frequency	Annual Savings	Net Annual Gain	Payback Period
0.5 per year (base case)	\$457,500	Positive	< 3 months
0.33 per year (1 per 3 years)	\$305,000		< 5 months
0.2 per year (1 per 5 years)	\$183,000		< 8 months

Even at one contamination event every five years, a frequency below most industry experience [9], IntuGrow delivers positive ROI within the first year and pays back the initial investment in seven months.